交易 Protagonist Therapeutics, Inc. - PTGX CFD
新增到我的最愛- 摘要
- 曆史數據
- 活動
- 盈虧控制
- 資産負債表
- 現金流
交易條件
價差 | 0.09 | ||||||||
多頭倉位隔夜費用
多頭隔夜費用
前往平台 | -0.026179% | ||||||||
空頭倉位隔夜費用
空頭隔夜費用
前往平台 | 0.003957% | ||||||||
隔夜費時間 | 21:00 (UTC) | ||||||||
最小成交量 | 1 | ||||||||
貨幣 | USD | ||||||||
保證金 | 5% | ||||||||
股票交易 | United States of America | ||||||||
交易委員會 | 0% |
*Information provided by Capital.com
Protagonist Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 拋售 | 自訂 | 變化 (%) | 打開 | 最高 | 最小 |
---|---|---|---|---|---|---|
Apr 19, 2024 | 25.56 | 0.46 | 1.83% | 25.10 | 25.58 | 24.72 |
Apr 18, 2024 | 25.17 | -0.09 | -0.36% | 25.26 | 25.68 | 25.00 |
Apr 17, 2024 | 25.51 | -0.55 | -2.11% | 26.06 | 26.19 | 25.30 |
Apr 16, 2024 | 26.05 | -0.12 | -0.46% | 26.17 | 26.29 | 25.84 |
Apr 15, 2024 | 26.52 | -0.51 | -1.89% | 27.03 | 27.26 | 26.25 |
Apr 12, 2024 | 27.02 | -0.37 | -1.35% | 27.39 | 27.48 | 26.62 |
Apr 11, 2024 | 27.63 | -0.24 | -0.86% | 27.87 | 28.03 | 27.31 |
Apr 10, 2024 | 27.83 | -0.35 | -1.24% | 28.18 | 28.44 | 27.69 |
Apr 9, 2024 | 29.10 | 1.83 | 6.71% | 27.27 | 29.15 | 27.27 |
Apr 8, 2024 | 28.03 | 0.10 | 0.36% | 27.93 | 28.07 | 27.29 |
Apr 5, 2024 | 27.96 | 0.69 | 2.53% | 27.27 | 28.54 | 26.85 |
Apr 4, 2024 | 27.60 | -0.18 | -0.65% | 27.78 | 28.87 | 27.50 |
Apr 3, 2024 | 28.03 | 0.51 | 1.85% | 27.52 | 28.35 | 27.52 |
Apr 2, 2024 | 27.96 | 0.28 | 1.01% | 27.68 | 28.05 | 27.27 |
Apr 1, 2024 | 28.23 | -0.47 | -1.64% | 28.70 | 28.75 | 27.59 |
Mar 28, 2024 | 28.87 | 1.02 | 3.66% | 27.85 | 29.21 | 27.48 |
Mar 27, 2024 | 28.41 | 0.33 | 1.18% | 28.08 | 28.56 | 27.90 |
Mar 26, 2024 | 27.94 | 0.02 | 0.07% | 27.92 | 28.27 | 27.52 |
Mar 25, 2024 | 27.83 | -0.05 | -0.18% | 27.88 | 28.38 | 27.58 |
Mar 22, 2024 | 27.97 | -0.18 | -0.64% | 28.15 | 28.29 | 27.78 |
Protagonist Therapeutics, Inc. Events
時間 (UTC) | 國家 | 事件 |
---|---|---|
Thursday, May 2, 2024 | ||
時間 (UTC) 10:59 | 國家 US
| 事件 Q1 2024 Protagonist Therapeutics Inc Earnings Release Q1 2024 Protagonist Therapeutics Inc Earnings ReleaseForecast(預報) -返回 - |
Friday, May 24, 2024 | ||
時間 (UTC) 17:00 | 國家 US
| 事件 Protagonist Therapeutics Inc Annual Shareholders Meeting Protagonist Therapeutics Inc Annual Shareholders MeetingForecast(預報) -返回 - |
Thursday, August 1, 2024 | ||
時間 (UTC) 20:00 | 國家 US
| 事件 Q2 2024 Protagonist Therapeutics Inc Earnings Release Q2 2024 Protagonist Therapeutics Inc Earnings ReleaseForecast(預報) -返回 - |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
總營業費用 | 157.954 | 153.202 | 93.729 | 80.752 | 73.194 |
銷售/一般/行政費用,總計 | 31.739 | 27.196 | 18.638 | 15.749 | 13.697 |
研究與開發 | 126.215 | 126.006 | 74.506 | 65.003 | 59.497 |
營業收入 | -131.373 | -125.845 | -65.101 | -80.521 | -42.269 |
利息收入(費用),非經營淨值 | 4.06 | 0.443 | 0.302 | 2.644 | 2.546 |
其他,淨值 | -0.08 | -0.149 | -0.046 | -0.001 | 0 |
稅前淨收入 | -127.393 | -125.551 | -64.845 | -77.878 | -39.723 |
稅後淨收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
未計算非常項目前的淨收益 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
淨收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Total Adjustments to Net Income | 0 | ||||
普通股股東可獲收益 (不含非經常性項目) | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
普通股股東可獲收益 (含非經常性項目) | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
攤薄淨收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
攤薄後加權平均股 | 49.0422 | 46.3229 | 34.3965 | 25.894 | 22.3645 |
扣除特別項目的每股攤薄盈利 | -2.59762 | -2.71034 | -1.92316 | -2.98088 | -1.74044 |
每股正常攤薄盈利 | -2.59762 | -2.71034 | -1.91211 | -2.98088 | -1.74044 |
收入 | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
非常規項目總計 | |||||
Dividends per Share - Common Stock Primary Issue | 0 | ||||
異常費用(收入) | 0 | 0 | 0.585 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 0 | 0 | 0 | 0 | 0.859 |
收入 | 0 | 0 | 0 | 0 | 0.859 |
總營業費用 | 42.354 | 36.021 | 36.516 | 32.303 | 42.302 |
銷售/一般/行政費用,總計 | 9.172 | 8.605 | 6.632 | 6.901 | 7.691 |
研究與開發 | 33.182 | 27.416 | 29.884 | 25.402 | 34.611 |
營業收入 | -42.354 | -36.021 | -36.516 | -32.303 | -41.443 |
利息收入(費用),非經營淨值 | 3.913 | 2.491 | 2.251 | 1.157 | 0.484 |
其他,淨值 | -0.019 | -0.195 | 0.071 | -0.086 | -0.078 |
稅前淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
稅後淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
未計算非常項目前的淨收益 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
普通股股東可獲收益 (不含非經常性項目) | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
普通股股東可獲收益 (含非經常性項目) | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
攤薄淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
攤薄後加權平均股 | 56.7757 | 50.5737 | 49.2549 | 49.1076 | 49.0499 |
扣除特別項目的每股攤薄盈利 | -0.6774 | -0.66685 | -0.69422 | -0.63599 | -0.83664 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.6774 | -0.66685 | -0.69422 | -0.63599 | -0.83664 |
異常費用(收入) | 0 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 243.077 | 340.736 | 315.606 | 145.311 | 137.503 |
現金和短期投資 | 237.355 | 326.9 | 305.809 | 133.017 | 128.853 |
現金等價物 | 125.744 | 123.665 | 117.358 | 33.006 | 82.233 |
短期投資 | 111.611 | 203.235 | 188.451 | 100.011 | 46.62 |
應收賬款總額,淨額 | 0.052 | 5.333 | 3.821 | 7.499 | 6.511 |
預付的費用 | 5.67 | 8.503 | 5.966 | 4.785 | 2.129 |
其他流動資産,總計 | 0.01 | 0.01 | 0.01 | ||
總資産 | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
物業/廠房/設備,總計 - 淨額 | 4.626 | 6.734 | 6.412 | 7.723 | 0.861 |
物業/廠房/設備,總計 - 總額 | 9.88 | 10.992 | 9.885 | 10.364 | 2.938 |
累計折舊,總計 | -5.254 | -4.258 | -3.473 | -2.641 | -2.077 |
長期投資 | 2 | ||||
其他長期資産,總計 | 0.225 | 0.225 | 0.45 | 1.883 | 1.108 |
流動負債總額 | 31.179 | 44.016 | 40.241 | 35.406 | 26.158 |
應付賬款 | 3.64 | 1.6 | 3.075 | 2.79 | 5.711 |
Payable/Accrued | |||||
預提費用 | 27.055 | 39.509 | 19.875 | 13.494 | 11.068 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
負債總額 | 32.32 | 47.674 | 44.862 | 74.953 | 26.957 |
長期債務總額 | 0 | 0 | 0 | 9.794 | 0 |
長期債務 | 0 | 9.794 | |||
股權 | 215.608 | 300.021 | 279.606 | 79.964 | 112.515 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
普通股 | 0.00049 | 0.00048 | 0.00044 | 0.00027 | 0 |
額外實收資本 | 752.722 | 709.682 | 563.389 | 297.846 | 253.222 |
留存收益(累計赤字) | -536.755 | -409.362 | -283.811 | -217.661 | -140.474 |
其他權益,總計 | -0.35949 | -0.29948 | 0.02756 | -0.22127 | -0.233 |
總負債和股東權益 | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
已發行普通股總數 | 49.3392 | 47.8383 | 43.7455 | 27.2176 | 23.1872 |
其他流動負債,總計 | 0.484 | 2.907 | 17.291 | 19.122 | 9.379 |
其他負債,總計 | 1.141 | 3.658 | 4.621 | 29.753 | 0.799 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 324.881 | 316.941 | 235.736 | 243.077 | 276.617 |
現金和短期投資 | 320.751 | 313.401 | 230.759 | 237.355 | 267.437 |
現金等價物 | 230.527 | 235.382 | 127.686 | 125.744 | 152.816 |
短期投資 | 90.224 | 78.019 | 103.073 | 111.611 | 114.621 |
應收賬款總額,淨額 | 0.065 | 0.05 | 0.051 | 0.052 | 0.62 |
預付的費用 | 4.065 | 3.49 | 4.926 | 5.67 | 8.56 |
總資産 | 330.016 | 320.466 | 239.858 | 247.928 | 282.174 |
物業/廠房/設備,總計 - 淨額 | 2.925 | 3.3 | 3.897 | 4.626 | 5.332 |
長期投資 | 1.985 | ||||
其他長期資産,總計 | 0.225 | 0.225 | 0.225 | 0.225 | 0.225 |
流動負債總額 | 27.867 | 26.398 | 23.229 | 31.179 | 36.754 |
應付賬款 | 1.252 | 4.573 | 4.021 | 3.64 | 4.715 |
預提費用 | 26.468 | 21.65 | 18.852 | 27.055 | 31.816 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 0.147 | 0.175 | 0.356 | 0.484 | 0.223 |
負債總額 | 27.867 | 26.398 | 23.691 | 32.32 | 38.558 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
其他負債,總計 | 0 | 0 | 0.462 | 1.141 | 1.804 |
股權 | 302.149 | 294.068 | 216.167 | 215.608 | 243.616 |
普通股 | 0.001 | 0.001 | 0.001 | 0.00049 | 0.00049 |
額外實收資本 | 945.363 | 903.205 | 786.768 | 752.722 | 746.657 |
留存收益(累計赤字) | -643.045 | -608.94 | -570.48 | -536.755 | -502.561 |
其他權益,總計 | -0.17 | -0.198 | -0.122 | -0.35949 | -0.48049 |
總負債和股東權益 | 330.016 | 320.466 | 239.858 | 247.928 | 282.174 |
已發行普通股總數 | 57.6475 | 57.4942 | 51.4405 | 49.3392 | 49.1984 |
其他流動資産,總計 | |||||
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
物業/廠房/設備,總計 - 總額 | 8.871 | 9.021 | 9.389 | 9.88 | 10.302 |
累計折舊,總計 | -5.946 | -5.721 | -5.492 | -5.254 | -4.97 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
淨收入/起跑線 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
經營活動産生的現金 | -108.137 | -107.865 | -72.484 | -41.527 | -49.947 |
經營活動産生的現金 | 1.034 | 0.813 | 0.789 | 0.703 | 0.527 |
非現金物品 | 25.988 | 20.187 | 10.455 | 9.588 | 7.125 |
營運資金的變化 | -7.766 | -3.314 | -19.016 | 26.144 | -18.017 |
投資活動産生的現金 | 91.468 | -15.86 | -90.965 | -53.71 | 2.213 |
資本支出 | -0.795 | -1.101 | -0.471 | -0.967 | -0.486 |
其他投資現金流量項目,總計 | 92.263 | -14.759 | -90.494 | -52.743 | 2.699 |
融資活動産生的現金 | 18.838 | 129.923 | 247.626 | 46.036 | 24.115 |
股票的發行(報廢),淨額 | 19.001 | 130.112 | 258.164 | 36.271 | 24.115 |
外彙效應 | -0.09 | -0.126 | 0.175 | -0.026 | -0.177 |
現金淨變化 | 2.079 | 6.072 | 84.352 | -49.227 | -23.796 |
Deferred Taxes | 0 | 1.438 | -0.775 | -0.658 | |
Cash Taxes Paid | 0 | 0 | 0.438 | 0.07 | |
債務的發行(退還),淨額 | 0 | -10.524 | 9.765 | ||
融資現金流項目 | -0.163 | -0.189 | -0.014 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -33.725 | -127.393 | -93.199 | -61.967 | -20.93 |
Cash From Operating Activities | -34.347 | -108.137 | -76.502 | -51.301 | -37.666 |
Cash From Operating Activities | 0.248 | 1.034 | 0.778 | 0.508 | 0.249 |
Non-Cash Items | 7.107 | 25.988 | 20.806 | 14.362 | 6.877 |
Changes in Working Capital | -7.977 | -7.766 | -4.887 | -4.204 | -23.862 |
Cash From Investing Activities | 9.826 | 91.468 | 87.533 | 30.258 | -4.476 |
Capital Expenditures | -0.01 | -0.795 | -0.725 | -0.563 | -0.273 |
Other Investing Cash Flow Items, Total | 9.836 | 92.263 | 88.258 | 30.821 | -4.203 |
Cash From Financing Activities | 26.463 | 18.838 | 18.285 | 17.605 | 16.925 |
Financing Cash Flow Items | -0.1 | -0.163 | -0.163 | -0.161 | -0.186 |
Issuance (Retirement) of Stock, Net | 26.563 | 19.001 | 18.448 | 17.766 | 17.111 |
Foreign Exchange Effects | 0 | -0.09 | -0.165 | 0.01 | 0.029 |
Net Change in Cash | 1.942 | 2.079 | 29.151 | -3.428 | -25.188 |
Deferred Taxes | 0 | ||||
Issuance (Retirement) of Debt, Net | 0 | ||||
Cash Taxes Paid | 0 |
差價合約交易計算器
計算您的假設損益
交易佣金
0
- 1:1
槓桿
1:1
- 20
- 100
- 500
- 1000
- 10000
交易
交易規模(槓桿 x 投資):
打開
拋售
已賣出 做多
Industry: | Biotechnology & Medical Research (NEC) |
7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US
盈虧控制
- Annual
- Quarterly
人們也觀看
還在尋找值得信賴的經紀商?
加入全球 610,000 多名交易者,選擇與 Capital.com 交易